First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

about

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

Item

http://www.wikidata.org/entity/Q52645845

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

First-in-human phase 1 study o ...... refractory B-cell NHL and CLL.

@en

First-in-human phase 1 study o ...... refractory B-cell NHL and CLL.

@nl

type

Item

label

First-in-human phase 1 study o ...... refractory B-cell NHL and CLL.

@en

First-in-human phase 1 study o ...... refractory B-cell NHL and CLL.

@nl

prefLabel

First-in-human phase 1 study o ...... refractory B-cell NHL and CLL.

@en

First-in-human phase 1 study o ...... refractory B-cell NHL and CLL.

@nl

P1476

First-in-human phase 1 study o ...... refractory B-cell NHL and CLL.

@en

P2093

Andy I Chen

http://www.w3.org/2001/XMLSchema#string

Ashley F Ward

http://www.w3.org/2001/XMLSchema#string

Bradley Augustson

http://www.w3.org/2001/XMLSchema#string

Elaine Murray

http://www.w3.org/2001/XMLSchema#string

Elicia Penuel

http://www.w3.org/2001/XMLSchema#string

Ian W Flinn

http://www.w3.org/2001/XMLSchema#string

Jeff Sharman

http://www.w3.org/2001/XMLSchema#string

Kwame Okrah

http://www.w3.org/2001/XMLSchema#string

Lichuan Liu

http://www.w3.org/2001/XMLSchema#string

Nina Wagner-Johnston

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Postibrutinib outcomes in patients with mantle cell lymphoma.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Rituximab in chronic lymphocytic leukemia.

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

P304

13023-13035

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24310

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

John C Byrd

P577

2018-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29560128

http://www.w3.org/2001/XMLSchema#string

P932

5849192

http://www.w3.org/2001/XMLSchema#string